

Michael H Woodworth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5354120/publications.pdf>

Version: 2024-02-01

38
papers

831
citations

623574

14
h-index

526166

27
g-index

40
all docs

40
docs citations

40
times ranked

1125
citing authors

#	ARTICLE	IF	CITATIONS
1	The gut microbiome's role in the development, maintenance, and outcomes of sepsis. <i>Critical Care</i> , 2020, 24, 278.	2.5	152
2	Fecal microbiota transplantation for the treatment of recurrent and severe <i>Clostridium difficile</i> infection in solid organ transplant recipients: A multicenter experience. <i>American Journal of Transplantation</i> , 2019, 19, 501-511.	2.6	101
3	Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. <i>Gut Microbes</i> , 2017, 8, 225-237.	4.3	77
4	Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1002-1010.	1.8	59
5	<i>Nocardia</i> infections in the transplanted host. <i>Transplant Infectious Disease</i> , 2018, 20, e12902.	0.7	45
6	Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent <i>Clostridium difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 1705-1711.	2.9	42
7	The Design of a Medical School Social Justice Curriculum. <i>Academic Medicine</i> , 2013, 88, 1442-1449.	0.8	40
8	The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	38
9	Microbial metabolite delta-valerobetaine is a diet-dependent obesogen. <i>Nature Metabolism</i> , 2021, 3, 1694-1705.	5.1	36
10	Increasing <i>Nocardia</i> Incidence Associated with Bronchiectasis at a Tertiary Care Center. <i>Annals of the American Thoracic Society</i> , 2017, 14, 347-354.	1.5	35
11	Fecal Microbiota Transplant for Refractory <i>Clostridium difficile</i> Infection Interrupts 25-Year History of Recurrent Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy016.	0.4	24
12	Fecal Microbiota Transplantation Is Safe and Effective in Patients With <i>Clostridioides difficile</i> Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	2.4	24
13	Predictors of Disease Severity in Patients Admitted to a Cholera Treatment Center in Urban Haiti. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 625-632.	0.6	18
14	Large scale enzyme based xenobiotic identification for exposomics. <i>Nature Communications</i> , 2021, 12, 5418.	5.8	18
15	Sentinel Case of <i>Candida auris</i> in the Western United States Following Prolonged Occult Colonization in a Returned Traveler from India. <i>Microbial Drug Resistance</i> , 2019, 25, 677-680.	0.9	12
16	Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers. <i>Transplant Infectious Disease</i> , 2021, 23, e13636.	0.7	12
17	Diagnostic Importance of Hyphae on Heart Valve Tissue in <i>Histoplasma</i> Endocarditis and Treatment With Isavuconazole. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx241.	0.4	10
18	Fecal Microbiota Transplant for Multidrug-Resistant Organism Decolonization Administered During Septic Shock. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 490-492.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Current Capabilities of Gut Microbiome-Based Diagnostics and the Promise of Clinical Application. <i>Journal of Infectious Diseases</i> , 2021, 223, S270-S275.	1.9	9
20	Disabling Dactylitis and Tenosynovitis Due to <i>Mycobacterium haemophilum</i> in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx165.	0.4	8
21	Ethical Considerations in Microbial Therapeutic Clinical Trials. <i>New Bioethics</i> , 2017, 23, 210-218.	0.5	7
22	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2021, , JCM0016121.	1.8	7
23	<i>Bergeyella cardium</i> : Clinical Characteristics and Draft Genome of an Emerging Pathogen in Native and Prosthetic Valve Endocarditis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz134.	0.4	6
24	Improving the Infectious Diseases Physician Scientist Workforce From the View of Junior Investigators: Vision, Transparency, and Reproducibility. <i>Clinical Infectious Diseases</i> , 2020, 70, 162-168.	2.9	6
25	Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection. <i>MSphere</i> , 2020, 5, .	1.3	6
26	Critical Care Management of the Patient with <i>Clostridioides difficile</i> . <i>Critical Care Medicine</i> , 2021, 49, 127-139.	0.4	6
27	Haemophagocytic lymphohistiocytosis associated with <i>Bartonella peliosis hepatis</i> following kidney transplantation in a patient with HIV. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e303-e309.	4.6	4
28	Validation of High-Sensitivity Severe Acute Respiratory Syndrome Coronavirus 2 Testing for Stool Toward the New Normal for Fecal Microbiota Transplantation. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00363.	1.3	3
29	Changes in treatment of community-onset <i>Clostridioides difficile</i> infection after release of updated guidelines, Atlanta, Georgia, 2018. <i>Anaerobe</i> , 2021, 70, 102364.	1.0	3
30	Durability and Long-Term Clinical Outcomes of Fecal Microbiota Transplant (FMT) Treatment in Patients with Recurrent <i>C. difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S384-S385.	0.4	2
31	Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection. <i>Transplant Infectious Disease</i> , 2018, 20, e12857.	0.7	2
32	Diagnostic and Therapeutic Considerations for Oncology Patients With <i>Clostridium difficile</i> Infection. <i>Journal of Oncology Practice</i> , 2017, 13, 31-32.	2.5	1
33	An Ounce of Prevention Is Equivalent to How Much Decolonization Exactly?. <i>Clinical Infectious Diseases</i> , 2021, 72, e924-e924.	2.9	1
34	<i>Nocardia</i> infections in the transplanted host. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
35	109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S1-S1.	0.4	0
36	mSphere of Influence: Microbiome-Associated Phenotypes Are Modifiable. <i>MSphere</i> , 2020, 5, .	1.3	0

#	ARTICLE	IF	CITATIONS
37	Are Patients Preferentially Receiving Oral Vancomycin for Clostridioides difficile Infection in 2018? A Population Perspective. Infection Control and Hospital Epidemiology, 2020, 41, s461-s462.	1.0	0
38	1078. Renal Transplant Recipient Resistomes Reveal Expansive Sub-Clinical Burden of Resistance After Treatment for ESBL-Producing Bacterial Infections. Open Forum Infectious Diseases, 2020, 7, S566-S567.	0.4	0